Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study

INTRODUCTION: Evaluating overall survival in randomized controlled trials (RCTs) can often be confounded by bias introduced by treatment switching. SERAPHIN was a large RCT that evaluated the effects of long-term treatment with the endothelin receptor antagonist macitentan in patients with pulmonary...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Scala, Lilla, Bacchi, Marisa, Bayer, Bjørn, Turricchia, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402487/
https://www.ncbi.nlm.nih.gov/pubmed/35917059
http://dx.doi.org/10.1007/s12325-022-02253-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402487/
https://www.ncbi.nlm.nih.gov/pubmed/35917059
http://dx.doi.org/10.1007/s12325-022-02253-8

Ejemplares similares